What type of study is this?

December 8, 2025BloodOpen Access

Barriers and bridges: Real-world CAR T delivery across US oncology practices

View Full Paper

Ask AI

Bookmark

Authors

TNTaiga NishihoriMoffitt Cancer Center

Discussion

Member takes

Implication

Observational analysis assessed car t utilization and overall survival among patients with mantle cell lymphoma, indicating access disparities in oncology settings.

Key Points

Overall survival from CAR T infusion was 26.3 months for DLBCL, indicating varying outcomes based on care settings.
Chimeric antigen receptor T-cell therapy utilization steadily increased, primarily at academic centers, with improved access noted in community practices.
Utilization of bridging therapies rose over time, with 67% usage in DLBCL and 75% in MM, highlighting changing treatment paradigms.
Access to CAR T therapy exhibited disparities, suggesting the need for equitable delivery models across academic and community oncology settings.

Cite This Study

Taiga Nishihori (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236deba https://doi.org/10.1182/blood-2025-6262

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis assessed car t utilization and overall survival among patients with mantle cell lymphoma, indicating access disparities in oncology settings.

Barriers and bridges: Real-world CAR T delivery across US oncology practices

Discussion

Member takes

Implication

Key Points

Cite This Study

Barriers and bridges: Real-world CAR T delivery across US oncology practices

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider